Trial · NCT01430403
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5]) | 90 Day outcome period | Intent-to-treat | Percent of adjusted prevalence | NUMBER |
| PRIMARY | Occurrence of One or More Asthma Exacerbations (Treatment Steps 2-4) | 90 Day outcome period | Intent-to-treat | Percent of adjusted prevalence | NUMBER |
| SECONDARY | Virus-induced Exacerbations as Measured by an Exacerbation That is Associated With a Virus Detected Using the Nasal Mucus Samples | 90 Day outcome period | Nasal mucus samples | Percent Samples with virus | NUMBER |
| SECONDARY | Severity of Asthma Symptoms Associated With a Viral Infection:Omalizumab vs. Placebo | 90 Day outcome period | The pre-specified intent for Outcome Measure: analysis inclusion limited to the Omalizumab and Placebo Groups.~Analysis: intent-to-treat (with available data). | Maximum Symptoms Days | MEAN |
| SECONDARY | Number of Exacerbations Evaluated Monthly With Viral Respiratory Infections: Omalizumab vs. Placebo | 90 Day outcome period | The pre-specified intent for Outcome Measure: analysis inclusion limited to the Omalizumab and Placebo Groups.~Analysis: intent-to-treat (with available data). | Total Number of Viral Infections | MEAN |
| SECONDARY | Composite Asthma Severity Index (CASI), Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat | CASI Score | MEAN |
| SECONDARY | Composite Asthma Severity Index (CASI), Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat with available CASI scores | CASI Score | MEAN |
| SECONDARY | Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted, Treatment Steps 2-5:Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat | percent predicted FEV1 | MEAN |
| SECONDARY | Spirometry Measurements: Forced Expiratory Volume in 1 Second (FEV1) % Predicted , Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat | percent predicted FEV1 | MEAN |
| SECONDARY | Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat | percent FEV1/FVC ratio | MEAN |
| SECONDARY | Spirometry Measurements: FEV1:FVCx100, Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat | percent FEV1/FVC ratio | MEAN |
| SECONDARY | Asthma Control Test Scores: Asthma Control Test (ACT), Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat with available ACT scores | ACT Score | MEAN |
| SECONDARY | Asthma Control Test Scores: Asthma Control Test (ACT), Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat with available ACT Scores | ACT Score | MEAN |
| SECONDARY | Asthma Control Test Score: Child Asthma Control Test (C-ACT), Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat with available C-ACT Scores | C-ACT Score | MEAN |
| SECONDARY | Asthma Control Test Score: Child Asthma Control Test (C-ACT), Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat with available C-ACT Scores | C-ACT Score | MEAN |
| SECONDARY | Work Disruptions Due to Child's Asthma, Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat with available data | Ratio | MEAN |
| SECONDARY | Work Disruptions Due to Child's Asthma, Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat with available data | Ratio | MEAN |
| SECONDARY | School Absences (Percent), Treatment Steps 2-5:Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat | Ratio | MEAN |
| SECONDARY | School Absences (Percent), Treatment Steps 2-4: Omalizumab vs. ICS | 90 Day outcome period | Intent-to-treat | Ratio | MEAN |
| SECONDARY | Percent Adherence to Asthma Medication, Treatment Steps 2-5: Omalizumab vs. Placebo | 90 Day outcome period | Intent-to-treat | percent adherence | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01430403/outcomes